Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Microbot Medical ( (MBOT) ) is now available.
On October 14, 2025, Microbot Medical announced a partnership with a U.S.-based third-party logistics company to aid the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System. The company plans a limited market release in the fourth quarter of 2025, with a broader launch expected in April 2026 at the Society of Interventional Radiology conference. This strategic partnership is intended to enhance Microbot Medical’s operational efficiency and market positioning by leveraging the logistics provider’s expertise in the medical device industry, ensuring effective inventory management and customer support.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety. Microbot Medical is committed to innovation and holds a strong intellectual property portfolio, driving the future of endovascular care.
Average Trading Volume: 4,301,154
Technical Sentiment Signal: Hold
Current Market Cap: $137.1M
See more data about MBOT stock on TipRanks’ Stock Analysis page.